cambridge's bluebird bio licenses delivery tech to novartis, gsk .
-
.
.
- it's the first successful medical treatment of a human fetus for the underlying cause of a genetic disorder, experts say .
- . .
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. . and prevention says hepatitis a is a vaccine-preventable, communicable disease of the liver caused by a virus. it is usually transmitted person-to-person or by consuming